Prospective and Mendelian randomization analyses on the association of circulating fatty acid binding protein 4 (FABP-4) and risk of colorectal cancer.

Nimptsch, Katharina; Kaaks, Rudolf; Schoen, Robert E; Yohar, Sandra Milena Colorado; Weiderpass, Elisabete; Harbs, Justin; Li, Christopher I; Pasanisi, Fabrizio; Pham, Thu Thi; Macciotta, Alessandra; Jenab, Mazda; van Guelpen, Bethany; Amiano, Pilar; Samadder, N Jewel; Tjønneland, Anne; Pischon, Tobias; Jakszyn, Paula Gabriela; Janke, Jürgen; Potter, John D; Papadimitriou, Nikos; Guevara, Marcela; Um, Caroline Y; Gunter, Marc J; Moreno, Victor; Christakoudi, Sofia; Palli, Domenico; Aleksandrova, Krasimira; Olsen, Anja; Heath, Alicia; Katzke, Verena; Grioni, Sara; Figueiredo, Jane C; Schulze, Matthias B

doi:10.1186/s12916-023-03104-1

Items
Marc 21

001			284767
005			20240229155055.0
024	7	_	\|a 10.1186/s12916-023-03104-1 \|2 doi
024	7	_	\|a pmid:37833736 \|2 pmid
024	7	_	\|a pmc:PMC10576353 \|2 pmc
024	7	_	\|a altmetric:155395871 \|2 altmetric
037	_	_	\|a DKFZ-2023-02078
041	_	_	\|a English
082	_	_	\|a 610
100	1	_	\|a Nimptsch, Katharina \|b 0
245	_	_	\|a Prospective and Mendelian randomization analyses on the association of circulating fatty acid binding protein 4 (FABP-4) and risk of colorectal cancer.
260	_	_	\|a Heidelberg [u.a.] \|c 2023 \|b Springer
336	7	_	\|a article \|2 DRIVER
336	7	_	\|a Output Types/Journal article \|2 DataCite
336	7	_	\|a Journal Article \|b journal \|m journal \|0 PUB:(DE-HGF)16 \|s 1697525301_8572 \|2 PUB:(DE-HGF)
336	7	_	\|a ARTICLE \|2 BibTeX
336	7	_	\|a JOURNAL_ARTICLE \|2 ORCID
336	7	_	\|a Journal Article \|0 0 \|2 EndNote
520	_	_	\|a Fatty acid binding protein 4 (FABP-4) is a lipid-binding adipokine upregulated in obesity, which may facilitate fatty acid supply for tumor growth and promote insulin resistance and inflammation and may thus play a role in colorectal cancer (CRC) development. We aimed to investigate the association between circulating FABP-4 and CRC and to assess potential causality using a Mendelian randomization (MR) approach.The association between pre-diagnostic plasma measurements of FABP-4 and CRC risk was investigated in a nested case-control study in 1324 CRC cases and the same number of matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A two-sample Mendelian randomization study was conducted based on three genetic variants (1 cis, 2 trans) associated with circulating FABP-4 identified in a published genome-wide association study (discovery n = 20,436) and data from 58,131 CRC cases and 67,347 controls in the Genetics and Epidemiology of Colorectal Cancer Consortium, Colorectal Cancer Transdisciplinary Study, and Colon Cancer Family Registry.In conditional logistic regression models adjusted for potential confounders including body size, the estimated relative risk, RR (95% confidence interval, CI) per one standard deviation, SD (8.9 ng/mL) higher FABP-4 concentration was 1.01 (0.92, 1.12) overall, 0.95 (0.80, 1.13) in men and 1.09 (0.95, 1.25) in women. Genetically determined higher FABP-4 was not associated with colorectal cancer risk (RR per FABP-4 SD was 1.10 (0.95, 1.27) overall, 1.03 (0.84, 1.26) in men and 1.21 (0.98, 1.48) in women). However, in a cis-MR approach, a statistically significant association was observed in women (RR 1.56, 1.09, 2.23) but not overall (RR 1.23, 0.97, 1.57) or in men (0.99, 0.71, 1.37).Taken together, these analyses provide no support for a causal role of circulating FABP-4 in the development of CRC, although the cis-MR provides some evidence for a positive association in women, which may deserve to be investigated further.
536	_	_	\|a 313 - Krebsrisikofaktoren und Prävention (POF4-313) \|0 G:(DE-HGF)POF4-313 \|c POF4-313 \|f POF IV \|x 0
588	_	_	\|a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650	_	7	\|a Colorectal cancer \|2 Other
650	_	7	\|a FABP-4 \|2 Other
650	_	7	\|a Mendelian randomization \|2 Other
700	1	_	\|a Aleksandrova, Krasimira \|b 1
700	1	_	\|a Pham, Thu Thi \|b 2
700	1	_	\|a Papadimitriou, Nikos \|b 3
700	1	_	\|a Janke, Jürgen \|b 4
700	1	_	\|a Christakoudi, Sofia \|b 5
700	1	_	\|a Heath, Alicia \|b 6
700	1	_	\|a Olsen, Anja \|b 7
700	1	_	\|a Tjønneland, Anne \|b 8
700	1	_	\|a Schulze, Matthias B \|b 9
700	1	_	\|a Katzke, Verena \|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 \|b 10 \|u dkfz
700	1	_	\|a Kaaks, Rudolf \|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a \|b 11 \|u dkfz
700	1	_	\|a van Guelpen, Bethany \|b 12
700	1	_	\|a Harbs, Justin \|b 13
700	1	_	\|a Palli, Domenico \|b 14
700	1	_	\|a Macciotta, Alessandra \|b 15
700	1	_	\|a Pasanisi, Fabrizio \|b 16
700	1	_	\|a Yohar, Sandra Milena Colorado \|b 17
700	1	_	\|a Guevara, Marcela \|b 18
700	1	_	\|a Amiano, Pilar \|b 19
700	1	_	\|a Grioni, Sara \|b 20
700	1	_	\|a Jakszyn, Paula Gabriela \|b 21
700	1	_	\|a Figueiredo, Jane C \|b 22
700	1	_	\|a Samadder, N Jewel \|b 23
700	1	_	\|a Li, Christopher I \|b 24
700	1	_	\|a Moreno, Victor \|b 25
700	1	_	\|a Potter, John D \|b 26
700	1	_	\|a Schoen, Robert E \|b 27
700	1	_	\|a Um, Caroline Y \|b 28
700	1	_	\|a Weiderpass, Elisabete \|b 29
700	1	_	\|a Jenab, Mazda \|b 30
700	1	_	\|a Gunter, Marc J \|b 31
700	1	_	\|a Pischon, Tobias \|b 32
773	_	_	\|a 10.1186/s12916-023-03104-1 \|g Vol. 21, no. 1, p. 391 \|0 PERI:(DE-600)2131669-7 \|n 1 \|p 391 \|t BMC medicine \|v 21 \|y 2023 \|x 1741-7015
909	C	O	\|o oai:inrepo02.dkfz.de:284767 \|p VDB
910	1	_	\|a Deutsches Krebsforschungszentrum \|0 I:(DE-588b)2036810-0 \|k DKFZ \|b 10 \|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910	1	_	\|a Deutsches Krebsforschungszentrum \|0 I:(DE-588b)2036810-0 \|k DKFZ \|b 11 \|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913	1	_	\|a DE-HGF \|b Gesundheit \|l Krebsforschung \|1 G:(DE-HGF)POF4-310 \|0 G:(DE-HGF)POF4-313 \|3 G:(DE-HGF)POF4 \|2 G:(DE-HGF)POF4-300 \|4 G:(DE-HGF)POF \|v Krebsrisikofaktoren und Prävention \|x 0
914	1	_	\|y 2023
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0501 \|2 StatID \|b DOAJ Seal \|d 2023-05-02T09:07:15Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0500 \|2 StatID \|b DOAJ \|d 2023-05-02T09:07:15Z
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b DOAJ : Open peer review \|d 2023-05-02T09:07:15Z
915	_	_	\|a WoS \|0 StatID:(DE-HGF)0113 \|2 StatID \|b Science Citation Index Expanded \|d 2023-09-03
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1190 \|2 StatID \|b Biological Abstracts \|d 2023-09-03
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0160 \|2 StatID \|b Essential Science Indicators \|d 2023-09-03
915	_	_	\|a Article Processing Charges \|0 StatID:(DE-HGF)0561 \|2 StatID \|d 2023-09-03
915	_	_	\|a Fees \|0 StatID:(DE-HGF)0700 \|2 StatID \|d 2023-09-03
915	_	_	\|a JCR \|0 StatID:(DE-HGF)0100 \|2 StatID \|b BMC MED : 2022 \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0200 \|2 StatID \|b SCOPUS \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0300 \|2 StatID \|b Medline \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0320 \|2 StatID \|b PubMed Central \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0600 \|2 StatID \|b Ebsco Academic Search \|d 2023-10-25
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b ASC \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0199 \|2 StatID \|b Clarivate Analytics Master Journal List \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1050 \|2 StatID \|b BIOSIS Previews \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0150 \|2 StatID \|b Web of Science Core Collection \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1110 \|2 StatID \|b Current Contents - Clinical Medicine \|d 2023-10-25
915	_	_	\|a IF >= 5 \|0 StatID:(DE-HGF)9905 \|2 StatID \|b BMC MED : 2022 \|d 2023-10-25
920	1	_	\|0 I:(DE-He78)C020-20160331 \|k C020 \|l C020 Epidemiologie von Krebs \|x 0
980	_	_	\|a journal
980	_	_	\|a VDB
980	_	_	\|a I:(DE-He78)C020-20160331
980	_	_	\|a UNRESTRICTED

Library	Collection	CLSMajor	CLSMinor	Language	Author

Marc 21

guest :: login DKFZ
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help